alt
Welcome
  • Funds

    Products

    • Mutual Funds
    • ETFs
    • SmartRetirement Funds
    • 529 Portfolios
    • Money Market Funds
    • Commingled Funds
    • Featured Funds

    Asset Class Capabilities

    • Fixed Income
    • Equity
    • Multi-Asset Solutions
    • Alternatives
    • Global Liquidity
  • Investment Strategies

    Investment Approach

    • ETF Investing
    • Separately Managed Accounts
    • Sustainable Investing
    • Variable Insurance Portfolios
    • Commingled Pension Trust Funds

    College Planning

    • 529 College Savings Plan
    • College Planning Essentials

    Defined Contribution

    • Retirement Solutions
    • Target Date Strategies
    • Full-service 401(k) Solution
    • Retirement Income
  • Insights

    Market Insights

    • Market Insights Overview
    • Guide to the Markets
    • Quarterly Economic & Market Update
    • Guide to Alternatives
    • Market Updates
    • Explore our latest resources
    • On the Minds of Investors
    • Principles for Successful Long-Term Investing
    • Weekly Market Recap

    Portfolio Insights

    • Portfolio Insights Overview
    • Asset Class Views
    • Equity
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Monthly Strategy Report
    • Sustainable Investing

    Retirement Insights

    • Retirement Insights Overview
    • Guide to Retirement
    • Principles for a Successful Retirement
    • Defined Contribution Insights
  • Tools

    Portfolio Construction

    • Portfolio Construction Tools Overview
    • Portfolio Analysis
    • Investment Comparison
    • Bond Ladder Illustrator

    Defined Contribution

    • Retirement Plan Tools & Resources Overview
    • Target Date Compass®
    • Core Menu Evaluator℠
    • Price Smart℠
  • Resources
    • Account Service Forms
    • Tax Planning
    • News & Fund Announcements
    • Insights App
    • Events
    • Library
  • About Us
  • Contact Us
Skip to main content
  • Account Login
    • Login
    • Register
  • Welcome
    • My Collections
    • Logout
  • Role
  • Country
  • Shareholder Login
Search
Menu
CLOSE
Search
You are about to leave the site Close
J.P. Morgan Asset Management’s website and/or mobile terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan Asset Management isn’t responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan Asset Management name.
CONTINUE Go Back
  1. Home
  2. Insights
  3. Market Insights
  4. Market Updates
  5. On the Minds of Investors
  6. How will the vaccine be distributed globally?

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print

How will the vaccine be distributed globally?

12/16/2020

Gabriela Santos

The distribution of the vaccine throughout the year should finally allow the depressed services sector of the global economy to bounce back strongly, and for countries that have been held hostage by the pandemic to return to normal.

Gabriela Santos

Gabriela Santos

Global Market Strategist

Listen to On the Minds of Investors

12/16/2020

2020 will be remembered as the year of the pandemic, while 2021 promises to be the year of the vaccine. The distribution of the vaccine throughout the year should finally allow the depressed services sector of the global economy to bounce back strongly and for countries that have been held hostage by the pandemic to return to normal. But how exactly will a vaccine be distributed globally to 7.8 billion people?

Thankfully, we have now taken the first momentous step: developing a safe and effective vaccine for COVID-19. So far, two vaccines have been approved by national regulatory agencies (Pfizer/BioNTech and Sinopharm-Beijing) and five others are in early/limited use (two Russian and three Chinese vaccines). In addition, 15 other vaccines are in large-scale final stages of testing, including three that may soon also receive approval (Moderna, University of Oxford/AstraZeneca, and Sinovac).

The challenge now lies in the manufacturing, distribution and acceptance of these vaccines. In the beginning, the available doses will be extremely limited and prioritization within the population will be crucial. However, as each month goes by, production is expected to increase substantially. Pfizer/BioNTech expect to produce globally 50 million vaccine doses in 2020, but 1.3 billion by the end of 2021. The more we see other vaccines approved, the faster the distribution can occur globally. In particular, the AstraZeneca vaccine would be key as it has double the purchase commitments as the second closest vaccine. The last piece of the puzzle is acceptance by the population. An October Ipsos poll showed a wide variation around the world of intentions to get vaccinated. Interestingly, emerging markets have the highest acceptance rate (India, China, South Korea, Brazil all above 80%), while developed countries have the lowest (Italy, Spain, U.S., and France all below 65%).

But when will the global economy go back to normal? One region of the world has not needed to wait for a vaccine to largely return to normal: North Asia. There, aggressive testing and contact tracing procedures have kept COVID cases low and activity high. Elsewhere, the timing of mass vaccine distribution is key – and this varies significantly country by country (chart below). Given deep pockets, high income countries have already purchased 3.9 billion doses of vaccines, while middle income countries have only purchased 2.8 billion doses (as estimated by the Duke Global Health Innovation Center). Unfortunately, low income countries have been left out and will depend entirely on global projects like COVAX. As a result, developed countries are expected reach critical mass vaccination in mid-2021, middle income countries by end-2021 or early 2022, and low income countries not until 2023 or 2024. 

Even though the vaccine may take longer to be distributed in certain EM regions, EM markets will react in advance of the reality on the ground. In particular, these markets have a high representation of cyclical sectors (at 54% of the MSCI Emerging Markets index), which should benefit from a strong global economic recovery and an improvement in global risk appetite. With that said, it is a long and winding road towards full vaccination. Investors should take care beneath the surface to invest in companies that will survive the pandemic to thrive in the post-vaccine world. 

Vaccination coverage and need varies around the world
% of population covered by confirmed doses (y-axis) and COVID-19 cases per million people (x-axis)

Source: Duke Global Health Innovation center. (2020). Launch and Scale Speedometer. Duke University. Data are as of December 15, 2020.


0903c02a82aaf189

Explore more

Stress test portfolios

The best portfolios stand strong when the markets don’t

Stress test portfolios now
purple bubbles

Aiming to be well positioned for future growth?

View solutions for growth
On the Minds of Investors podcast

On the minds of investors

View all
Global economy Markets US economy
J.P. Morgan Asset Management

  • Capital Gains Distributions
  • eDelivery
  • Fund Documents
  • Glossary
  • Help
  • How to invest
  • Important Links
  • Mutual Fund Fee Calculator
  • Accessibility
  • Investment stewardship
  • Stewardship priorities
  • Privacy
  • Proxy Information
  • Senior Officer Fee Summary
  • SIMPLE IRAs
  • Site disclaimer
  • Terms of use
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase
Opens LinkedIn site in new window Opens Youtube site in new window Opens Twitter site in new window

This website is a general communication being provided for informational purposes only. It is educational in nature and not designed to be a recommendation for any specific investment product, strategy, plan feature or other purposes. By receiving this communication you agree with the intended purpose described above. Any examples used in this material are generic, hypothetical and for illustration purposes only. None of J.P. Morgan Asset Management, its affiliates or representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. Communications such as this are not impartial and are provided in connection with the advertising and marketing of products and services. Prior to making any investment or financial decisions, an investor should seek individualized advice from personal financial, legal, tax and other professionals that take into account all of the particular facts and circumstances of an investor's own situation.

 

Opinions and statements of financial market trends that are based on current market conditions constitute our judgment and are subject to change without notice. We believe the information provided here is reliable but should not be assumed to be accurate or complete. The views and strategies described may not be suitable for all investors.

 

INFORMATION REGARDING MUTUAL FUNDS/ETF:

 

Investors should carefully consider the investment objectives and risks as well as charges and expenses of a mutual fund or ETF before investing. The summary and full prospectuses contain this and other information about the mutual fund or ETF and should be read carefully before investing. To obtain a prospectus for Mutual Funds: Contact JPMorgan Distribution Services, Inc. at 1-800-480-4111 or download it from this site. Exchange Traded Funds: Call 1-844-4JPM-ETF or download it from this site.

 

J.P. Morgan Funds and J.P. Morgan ETFs are distributed by JPMorgan Distribution Services, Inc., which is an affiliate of JPMorgan Chase & Co. Affiliates of JPMorgan Chase & Co. receive fees for providing various services to the funds. JPMorgan Distribution Services, Inc. is a member of FINRA  FINRA's BrokerCheck

 

INFORMATION REGARDING COMMINGLED FUNDS:

 

For additional information regarding the Commingled Pension Trust Funds of JPMorgan Chase Bank, N.A., please contact your J.P. Morgan Asset Management representative.

 

The Commingled Pension Trust Funds of JPMorgan Chase Bank N.A. are collective trust funds established and maintained by JPMorgan Chase Bank, N.A. under a declaration of trust. The funds are not required to file a prospectus or registration statement with the SEC, and accordingly, neither is available. The funds are available only to certain qualified retirement plans and governmental plans and is not offered to the general public. Units of the funds are not bank deposits and are not insured or guaranteed by any bank, government entity, the FDIC or any other type of deposit insurance. You should carefully consider the investment objectives, risk, charges, and expenses of the fund before investing.

 

INFORMATION FOR ALL SITE USERS:

 

J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

 

NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE

 

Telephone calls and electronic communications may be monitored and/or recorded.
Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://www.jpmorgan.com/privacy.

 

If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance. 

 

Copyright © 2021 JPMorgan Chase & Co., All rights reserved